Epidemiology of Biomarkers of AMD Progression
AMD 进展生物标志物的流行病学
基本信息
- 批准号:10489288
- 负责人:
- 金额:$ 58.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgeAge YearsAge related macular degenerationAmishAngiogenesis InhibitorsAngiographyAtrophicBackground Diabetic RetinopathyBiological MarkersBlindnessCalibrationChoroidChoroidal NeovascularizationClassificationClinicClinicalClinical ResearchClinical TrialsColorDataDepositionDevelopmentDiabetic RetinopathyDiseaseDrusenEarly InterventionElderlyEpidemiologyEvolutionEyeEye diseasesFilmFunctional disorderFundingFundusGeneticGenetic MarkersGenetic VariationImageImaging technologyIndividualInterventionIntervention TrialKnowledgeMethodsModelingModernizationMultimodal ImagingNonexudative age-related macular degenerationOptical Coherence TomographyOutcome AssessmentPatientsPhasePhenotypePopulationPopulation StudyPrincipal Component AnalysisProbabilityProtocols documentationResearchResearch PersonnelResourcesRetinaRiskRisk FactorsSeriesSeveritiesSeverity of illnessStagingStaging SystemSystemTechniquesTestingTherapeutic TrialsTimeUncertaintyUnited StatesValidationVisitage relatedclinical practicecohortcostdeep learningdesigndigital imagingeffective therapyeffectiveness evaluationepidemiology studyfollow-upgenetic risk factorgeographic atrophyhigh riskimprovedinsightlearning algorithmmaculaneovascularizationnovelpopulation basedpreventprogression riskrecruitrisk variantsocialstatistical learningsuccesstherapy developmentthree-dimensional visualization
项目摘要
Project Abstract
There are currently no effective treatments for atrophic age-related macular degeneration (AMD), in part
because we may be intervening too late in the disease course after geographic atrophy (GA) has developed. A
far preferable strategy would be to intervene at an earlier phase of the disease, but there is uncertainty with
regards to disease biomarkers to select the most appropriate patients as well as endpoints which could be
used to conduct an interventional trial in a clinically-practical time-frame. This is in large part because of the
lack of a sufficiently granular staging system describing the progression from early to late stage AMD. The best
currently available data comes from studies such as the Age-Related Eye Diseases Study and the Beaver
Dam Eye Study, but these studies were largely based on color fundus photographs with AMD disease features
assessed using historical protocols developed in the film-based imaging era. The AMD disease severity scales
and staging systems built from these studies are insufficiently granular and fail to take advantage of modern,
pervasive digital imaging technologies such as optical coherence tomography (OCT) and OCT angiography
(OCT-A) which readily lend themselves to quantification. Extensive research over the past decade has
identified a number of structural OCT features of AMD, such as intraretinal hyper-reflective foci and subretinal
drusenoid deposits, which appear to increase the risk for developing late AMD (atrophy and/or
neovascularization). More recently, choriocapillaris (CC) flow deficits have been shown to increase with age
and in AMD. The relationship between CC flow deficits and the onset and stage of AMD still remains to be
defined. In addition, although a number of genetic risk factors for AMD have been identified, the genetics of
AMD progression are not yet elucidated. This research application proposes to address these critical
knowledge gaps by evaluating elderly subjects with AMD who have previously been recruited as part of the
NEI-funded Amish Eye Study. The Amish represent a homogenous population with regards to environmental
and social exposures which reduces variability and makes this group ideally suited for epidemiologic studies of
AMD progression. Through that previous study, baseline (and some 2-year follow up) clinical, multimodal
imaging (including OCT), and genetic data have already been collected. However, long-term (7 year) data,
which will be a focus of our proposed research, is critical to actually establish which individuals go on to
progress to late AMD, which is vital in order to determine which baseline features are associated with a higher
risk of progression, and to develop a granular and quantitative staging system for AMD. The development of
this novel AMD staging system will provide points of intervention and outcome assessment to enable
early intervention clinical trials and provide new insights into the genetics and pathophysiology of
AMD.
项目摘要
目前对于萎缩性年龄相关性黄斑变性(AMD)没有有效的治疗方法,部分原因是
因为在地图状萎缩(GA)发展后,我们可能干预得太晚了。一
更可取的策略是在疾病的早期阶段进行干预,但
关于疾病生物标志物,以选择最合适的患者以及可能
用于在临床实用的时间范围内进行干预性试验。这主要是因为
缺乏描述从早期到晚期AMD进展的足够粒度的分期系统。最好的
目前可用的数据来自于一些研究,如与眼睛相关的眼病研究和海狸研究。
Dam Eye Study,但这些研究主要基于具有AMD疾病特征的彩色眼底照片
使用基于胶片的成像时代开发的历史协议进行评估。AMD疾病严重程度量表
从这些研究中建立的分期系统不够精细,
普及的数字成像技术,如光学相干断层扫描(OCT)和OCT血管造影
(OCT-A)很容易量化。过去十年的广泛研究
确定了AMD的许多结构OCT特征,例如视网膜内高反射灶和视网膜下高反射灶。
玻璃疣样沉积物,这似乎增加了发展晚期AMD的风险(萎缩和/或
新血管形成)。最近,脉络膜毛细血管(CC)流量赤字已被证明随着年龄的增长而增加
在AMD CC血流缺损与AMD的发病和分期的关系仍有待进一步研究
定义了此外,尽管已经确定了AMD的许多遗传风险因素,但AMD的遗传学特征仍然存在。
AMD进展尚未阐明。本研究旨在解决这些关键问题。
通过评估先前作为研究的一部分招募的老年AMD受试者,
NEI资助的Amish眼科研究。阿米什人在环境方面是一个同质的群体
和社会暴露,减少了变异性,使这一群体非常适合流行病学研究,
AMD进展。通过先前的研究,基线(和一些2年随访)临床,多模式
成像(包括OCT)和遗传数据已经收集。然而,长期(7年)数据,
这将是我们拟议研究的重点,对于实际确定哪些人会继续
进展到晚期AMD,这对于确定哪些基线特征与更高的AMD相关至关重要。
风险的进展,并制定一个粒度和定量分期系统的AMD。的发展
这种新的AMD分期系统将提供干预点和结果评估,
早期干预临床试验,并提供新的见解,遗传学和病理生理学的
AMD.
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of OCT B-Scan Density on Sensitivity for Detection of Intraretinal Hyperreflective Foci in Eyes with Age-Related Macular Degeneration.
- DOI:10.1080/02713683.2022.2081981
- 发表时间:2022-09
- 期刊:
- 影响因子:2
- 作者:
- 通讯作者:
Longitudinal evaluation of the distribution of intraretinal hyper-reflective foci in eyes with intermediate age-related macular degeneration.
中度年龄相关性黄斑变性眼视网膜内高反射灶分布的纵向评估。
- DOI:10.21203/rs.3.rs-3273570/v1
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Sadda,Srinivas;Verma,Aditya;Corradetti,Giulia;Nittala,Muneeswar;He,Ye;Nassisi,Marco;Velaga,SwethaBindu;Haines,Jonathan;Pericak-Vance,Margaret;Stambolian,Dwight
- 通讯作者:Stambolian,Dwight
Enhanced Detection of Reticular Pseudodrusen on Color Fundus Photos by Image Embossing.
- DOI:10.1080/02713683.2022.2126860
- 发表时间:2022-11
- 期刊:
- 影响因子:2
- 作者:
- 通讯作者:
Drusen morphometrics on optical coherence tomography in eyes with age-related macular degeneration and normal aging.
- DOI:10.1007/s00417-023-06088-z
- 发表时间:2023-09
- 期刊:
- 影响因子:2.7
- 作者:Oncel, Deniz;Corradetti, Giulia;Wakatsuki, Yu;Nittala, Muneeswar Gupta;Velaga, Swetha Bindu;Stambolian, Dwight;Pericak-Vance, Margaret A.;Haines, Jonathan L.;Sadda, SriniVas R.
- 通讯作者:Sadda, SriniVas R.
Risk Factors for Progression of Age-Related Macular Degeneration: Population-Based Amish Eye Study.
- DOI:10.3390/jcm11175110
- 发表时间:2022-08-30
- 期刊:
- 影响因子:3.9
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan L Haines其他文献
Jonathan L Haines的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan L Haines', 18)}}的其他基金
Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL
阿米什人阿尔茨海默病的保护性遗传变异 - RENEWAL
- 批准号:
10448612 - 财政年份:2022
- 资助金额:
$ 58.26万 - 项目类别:
Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL
阿米什人阿尔茨海默病的保护性遗传变异 - RENEWAL
- 批准号:
10689703 - 财政年份:2022
- 资助金额:
$ 58.26万 - 项目类别:
Protective Genetic Variants for Alzheimer Disease in the Amish
阿米什人阿尔茨海默病的保护性遗传变异
- 批准号:
9898659 - 财政年份:2017
- 资助金额:
$ 58.26万 - 项目类别:
Protective Genetic Variants for Alzheimer Disease in the Amish
阿米什人阿尔茨海默病的保护性遗传变异
- 批准号:
9439190 - 财政年份:2017
- 资助金额:
$ 58.26万 - 项目类别:
Advancing Genetics Through the AMDgene Consortium
通过 AMDgene 联盟推进遗传学发展
- 批准号:
8265101 - 财政年份:2012
- 资助金额:
$ 58.26万 - 项目类别:
Advancing Genetics Through the AMDgene Consortium
通过 AMDgene 联盟推进遗传学发展
- 批准号:
8449079 - 财政年份:2012
- 资助金额:
$ 58.26万 - 项目类别:
Advancing Genetics Through the AMDgene Consortium
通过 AMDgene 联盟推进遗传学发展
- 批准号:
8655882 - 财政年份:2012
- 资助金额:
$ 58.26万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 58.26万 - 项目类别:
Research Grant














{{item.name}}会员




